The Journey Leading to an Approved NDA

The initial scope of this project involved the authorship and delivery of several key documents, including a Pre-NDA Meeting Package designed to outline essential discussion points and gather feedback from regulatory authorities, as well as five comprehensive Clinical Study Reports (CSRs) that evaluated safety and efficacy. Additionally, we drafted key clinical components of the NDA, such as the Integrated Summaries of Efficacy and Safety (ISE and ISS), Summaries of Clinical Efficacy and Safety (Modules 2.7.3 and 2.7.4), and the Clinical Overview (Module 2.5).

Our team of experts oversaw the entire NDA process, effectively coordinating medical writing and quality control activities to ensure accuracy, timeliness, and compliance across all documentation. We collaborated with the client’s third-party biostatistics vendor to create statistical analysis plans and produce clear final tables, listings, and figures. Additionally, we partnered with the company’s electronic publishing vendor to ensure all documents were compiled on time and ready for submission.

Beyond our writing efforts, we worked closely with the client to develop key messaging points that needed to be integrated into all submission documents, reinforcing the rationale behind the proposed label. Our Project Manager offered insights on navigating complex clinical and regulatory challenges within the application, helping to identify solutions that increased the chances of a successful outcome.

Throughout the project, Syner-G built a strong, collaborative relationship with the client, becoming a trusted extension of their team. Our client’s commitment to addressing a significant unmet medical need enabled the successful launch of a drug that enhances the lives of patients who have long lacked effective treatment options. By working together, we successfully navigated regulatory complexities, secured agency approval, and ensured a successful market launch that will have a meaningful impact on patient care.